Rafael Holdings Reports Widened Losses and Material Weakness in Financial Controls
RFL sits 17% above its 52-week low of $1.12.
Summary
Rafael Holdings reported increased Q2 losses and a material weakness in internal controls at its acquired Cyclo subsidiary, alongside a significant rise in R&D spending. Cash reserves are projected to last at least 12 months, with a notable debt settlement expected to boost Q3 results.
Key Events · Earnings and Guidance · RFL
-
Increased Net Loss
Net loss attributable to Rafael Holdings, Inc. widened to $(6.4) million for the second quarter and $(16.2) million for the six months ended January 31, 2026, compared to $(4.6) million and $(13.6) million in the prior year periods, respectively.
-
Surge in Research and Development Expenses
Research and development expenses significantly increased to $4.5 million for Q2 2026 and $12.0 million for the six months, primarily due to the inclusion of Cyclo's R&D activities post-merger.
-
Material Weakness in Internal Controls Identified
Management identified a material weakness in internal control over financial reporting at its wholly-owned subsidiary, Cyclo, related to accruals and expenses, particularly clinical trial accruals. A remediation plan is currently underway.
-
Decreased Cash Position with Stated Liquidity
Cash and cash equivalents decreased to $37.8 million as of January 31, 2026, from $52.8 million at July 31, 2025. The company expects this balance to be sufficient to meet its obligations for at least the next 12 months.
Analysis · RFL · Life Sciences
Rafael Holdings, Inc. reported a significant increase in net losses for the second quarter and first six months of fiscal 2026, primarily driven by a substantial rise in research and development expenses following the merger with Cyclo. While the company maintains a cash runway for at least the next 12 months, the increased cash burn is notable. A material weakness in internal controls related to the acquired Cyclo subsidiary's accruals and expenses presents a compliance risk, though a remediation plan is in progress. Positively, subsequent to the reporting period, the company settled a significant creditor liability for a fraction of its carrying value, which is expected to result in a substantial non-cash gain in the next quarter.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.9% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RFL was trading at $1.31 on NYSE in the Life Sciences sector, with a market capitalization of approximately $67.8M. The 52-week trading range was $1.12 to $3.19. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.